Interview with Michael Pehl, Managing Director, Celgene Germany
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Address: Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany
Tel: + 49 30 726247-0
NOXXON Pharma AG is an independent biopharmaceutical company focusing on the development of innovative pharmaceutical products based on its unique proprietary Spiegelmer® Technology. The company is concentrating its attention on inflammatory diseases and haematological conditions. NOXXON’s lead compound, NOX-E36 for treatment of kidney inflammation, is currently undergoing phase I clinical testing. A second Spiegelmer compound, NOX A12 for use in stem cell transplantation, is scheduled to enter phase I clinical testing later this year.NOXXON’s goal is the in-house development of our own Spiegelmer products through Phase II clinical trials. Complementing its own programs, NOXXON works on multiple drug discovery and development projects with its partners Eli Lilly, F. Hoffmann-La Roche, and Pfizer. The pursuit of licensing partnerships and collaborative Research & Development efforts is an integral part of our business strategy and plays an important role in the company’s growth and success. This strategy reflects our strengths in drug discovery and the vast potential of our unique technology platform.
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Cytonet is today Germany’s largest cell therapy enterprise. However, it went through many transformations since its spin-off from Roche Diagnostics in 2000. Could you briefly introduce the company to our…
The German Pharmaceutical Industry is not only known for its cutting-edge R&D and production base but also for having a high penetration of generics. In your opinion, what role do…
See our Cookie Privacy Policy Here
